Your session is about to expire
← Back to Search
JNJ-77242113 for Plaque Psoriasis
Study Summary
This trial aims to see how well JNJ-77242113 works for people with moderate to severe plaque psoriasis when compared to a placebo and deucravacitinib.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowExclusion Criteria
You may be eligible for the trial if you check “No” for criteria below:Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Logistics
Other reimbursement is provided
Other forms of reimbursement are provided for this trial.
Who is running the clinical trial?
Frequently Asked Questions
Has the medication JNJ-77242113 received approval from the FDA?
"Based on the fact that this trial is in Phase 3 and has accumulated multiple rounds of safety data along with some evidence of efficacy, our team at Power rates the safety of JNJ-77242113 as a 3."
Are there any ongoing efforts to enroll participants in this medical study at the moment?
"As per the details provided on clinicaltrials.gov, this research trial is presently seeking participants. It was first listed on March 9th, 2024 and underwent its most recent revision on April 23rd, 2024."
At how many sites is this particular research study currently being conducted?
"At the moment, 98 sites are actively enrolling participants for this research. These establishments are strategically located in Miami, Encino, and Bay City alongside several other locations. Opting for a nearby facility is crucial to reduce travel commitments if you choose to take part."
What is the upper limit on the number of individuals enrolled in this clinical trial?
"A total of 675 eligible participants meeting the defined criteria are required for enrollment in this research. Interested individuals may join from various sites, such as Bioclinical Research Alliance Inc. situated in Miami, Florida, and T Joseph Raoof Md Inc. located in Encino, California."
Share this study with friends
Copy Link
Messenger